Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom. / Fløe, Louise Elkjær; Svane, Inge Marie; Bastholt, Lars; Schmidt, Henrik.

In: Ugeskrift for Laeger, Vol. 178, V01160070, 2016.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Fløe, LE, Svane, IM, Bastholt, L & Schmidt, H 2016, 'Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom', Ugeskrift for Laeger, vol. 178, V01160070. <http://ugeskriftet.dk/videnskab/immuncheckpointantistoffer-oeger-overlevelsen-patienter-med-metastatisk-melanom>

APA

Fløe, L. E., Svane, I. M., Bastholt, L., & Schmidt, H. (2016). Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom. Ugeskrift for Laeger, 178, [V01160070]. http://ugeskriftet.dk/videnskab/immuncheckpointantistoffer-oeger-overlevelsen-patienter-med-metastatisk-melanom

Vancouver

Fløe LE, Svane IM, Bastholt L, Schmidt H. Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom. Ugeskrift for Laeger. 2016;178. V01160070.

Author

Fløe, Louise Elkjær ; Svane, Inge Marie ; Bastholt, Lars ; Schmidt, Henrik. / Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom. In: Ugeskrift for Laeger. 2016 ; Vol. 178.

Bibtex

@article{3fa8b083af994490bf5ea516165d0a85,
title = "Immuncheckpointantistoffer {\o}ger overlevelsen for patienter med metastatisk melanom",
abstract = "The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.",
keywords = "English Abstract, Journal Article",
author = "Fl{\o}e, {Louise Elkj{\ae}r} and Svane, {Inge Marie} and Lars Bastholt and Henrik Schmidt",
year = "2016",
language = "Dansk",
volume = "178",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

AU - Fløe, Louise Elkjær

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Schmidt, Henrik

PY - 2016

Y1 - 2016

N2 - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

AB - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 27550784

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V01160070

ER -

ID: 181026728